Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells

Prostate

Volumn 72, Issue 4, 2012, Pages 450-460

  Thomas, Lynn N ^a   Morehouse, Timothy J ^a   Too, Catherine K L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

carboxypeptidase D; nitric oxide; prolactin; prostate cancer; testosterone

Indexed keywords

ANDROSTANOLONE; CARBOXYPEPTIDASE D; NITRIC OXIDE; PROLACTIN; SMALL INTERFERING RNA; TESTOSTERONE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; APOPTOSIS; ARGININE; CARBOXYPEPTIDASES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; NITRIC OXIDE; PROLACTIN; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TESTOSTERONE; UP-REGULATION;

EID: 84855674396     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21446     Document Type: Article

References (51)

1. Skidgel RA, Erdos EG,. Cellular carboxypeptidases. Immunol Rev 1998; 161: 129-141.
2. Song L, Fricker LD,. Purification and characterization of carboxypeptidase D, a novel carboxypeptidase E-like enzyme, from bovine pituitary. J Biol Chem 1995; 270 (42): 25007-25013.
3. Song L, Fricker LD,. Tissue distribution and characterization of soluble and membrane-bound forms of metallocarboxypeptidase D. J Biol Chem 1996; 271 (46): 28884-28889. (Pubitemid 26382588)
4. Varlamov O, Fricker LD,. Intracellular trafficking of metallocarboxypeptidase D in AtT-20cells: Localization to the trans-Golgi network and recycling from the cell surface. J Cell Science 1998; 111 (Pt 7): 877-885. (Pubitemid 28196071)
5. O'Malley PG, Sangster SM, Abdelmagid SA, Bearne SL, Too CKL,. Characterization of a novel, cytokine-inducible carboxypeptidase D isoform in haematopoietic tumour cells. Biochem J 2005; 390 (Pt 3): 665-673. (Pubitemid 41395348)
6. Keskinege A, Elgun S, Yilmaz E,. Possible implications of arginase and diamine oxidase in prostatic carcinoma. Cancer Detect Prev 2001; 25 (1): 76-79.
7. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW,. Expression of arginase II in prostate cancer. Intl J Oncol 2008; 32 (2): 357-365. (Pubitemid 351188302)
8. Beckman JS, Koppenol WH,. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996; 271 (5 Pt 1): C1424-C1437.
9. Thomsen LL, Miles DW,. Role of nitric oxide in tumour progression: Lessons from human tumours. Cancer Metastasis Rev 1998; 17 (1): 107-118. (Pubitemid 28194649)
10. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK,. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Intl J Cancer 1999; 81 (6): 889-896. (Pubitemid 29249973)
11. Jadeski LC, Lala PK,. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155 (4): 1381-1390. (Pubitemid 29488945)
12. Aaltoma SH, Lipponen PK, Kosma VM,. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001; 21 (4B): 3101-3106. (Pubitemid 33051183)
13. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A,. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 2009; 119 (5): 1093-1108.
14. Hadkar V, Skidgel RA,. Carboxypeptidase D is up-regulated in RAW 264.7 macrophages and stimulates nitric oxide synthesis by cells in arginine-free medium. Mol Pharmacol 2001; 59 (5): 1324-1332. (Pubitemid 32381612)
15. Hadkar V, Sangsree S, Vogel SM, Brovkovych V, Skidgel RA,. Carboxypeptidase-mediated enhancement of nitric oxide production in rat lungs and microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287 (1): L35-L45. (Pubitemid 38787648)
16. Abdelmagid SA, Too CKL,. Prolactin and estrogen up-regulate carboxypeptidase-D to promote nitric oxide production and survival of MCF-7 breast cancer cells. Endocrinology 2008; 149 (10): 4821-4828.
17. Too CKL, Vickaryous N, Boudreau RT, Sangster SM,. Identification and nuclear localization of a novel prolactin and cytokine-responsive carboxypeptidase D. Endocrinology 2001; 142 (3): 1357-1367. (Pubitemid 32202849)
18. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP,. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genetics 1995; 9 (4): 401-406.
19. George FW, Johnson L, Wilson JD,. The effect of a 5α-reductase inhibitor on androgen physiology in the immature male rat. Endocrinology 1989; 125 (5): 2434-2438. (Pubitemid 19279428)
20. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, Ramirez de Arellano E, Kazam E,. Prostate visualization studies in males homozygous and heterozygous for 5a-reductase deficiency. J Clin Endocrinol Metab 1992; 75 (4): 1022-1026.
21. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC,. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001; 57 (4 Suppl. 1) 46-51.
22. Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS, Too CKL,. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008; 179 (1): 147-151. (Pubitemid 350216746)
23. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS,. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. The Prostate 2005; 63 (3): 231-239. (Pubitemid 40571057)
24. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, Naito M,. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61 (4): 448-454. (Pubitemid 351518226)
25. Thomas LN, Douglas RC, Rittmaster RS, Too CKL,. Overexpression of 5α-reductase Type 1 causes increased sensitivity to low concentrations of testosterone in LnGK9 prostate cancer cells. The Prostate 2009; 69 (6): 595-602.
26. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL,. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 1996; 137 (7): 3078-3088. (Pubitemid 26192207)
27. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM,. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999; 154 (3): 863-870. (Pubitemid 29122605)
28. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL,. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997; 99 (4): 618-627. (Pubitemid 27097662)
29. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT,. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004; 64 (14): 4774-4782. (Pubitemid 38924520)
30. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT,. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007; 148 (7): 3089-3101. (Pubitemid 46996970)
31. Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT,. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 2002; 143 (1): 228-238. (Pubitemid 34056424)
32. Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H,. Epithelial defect in prostates of Stat5a-null mice. Lab Invest 2000; 80 (7): 993-1006. (Pubitemid 30483218)
33. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT,. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003; 278 (29): 27287-27292. (Pubitemid 36876886)
34. Dagvadorj A, Tan SH, Liao Z, Cavalli LR, Haddad BR, Nevalainen MT,. Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin Cancer Res 2008; 14 (19): 6062-6072.
35. Dodd F, Limoges M, Boudreau RT, Rowden G, Murphy PR, Too CKL,. L-arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells. J Cell Biochem 2000; 77 (4): 624-634. (Pubitemid 30332002)
36. Brinkmann AO, Kuiper GG, Bolt-de Vries J, Mulder E,. In situ photolabelling of the human androgen receptor. J Steroid Biochem 1988; 30 (1-6): 257-261.
37. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J,. Androgen receptors in endocrine-therapy- resistant human prostate cancer. Int J Cancer 1991; 48 (2): 189-193.
38. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP,. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 1995; 332 (21): 1393-1398.
39. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP,. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57 (2): 314-319. (Pubitemid 27036612)
40. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61 (11): 4315-4319. (Pubitemid 32685750)
41. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT,. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999; 140 (11): 5412-5421.
42. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT,. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008; 68 (1): 236-248. (Pubitemid 351380125)
43. Thomas LN, Douglas RC, Lazier CB, Too CKL, Rittmaster RS, Tindall DJ,. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53 (2): 244-252. (Pubitemid 350296595)
44. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S,. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995; 92 (10): 4392-4396.
45. Fukumura D, Kashiwagi S, Jain RK,. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6 (7): 521-534. (Pubitemid 43980541)
46. Wang D, Lu S, Dong Z,. Regulation of TGF-beta1 gene transcription in human prostate cancer cells by nitric oxide. The Prostate 2007; 67 (16): 1825-1833. (Pubitemid 350228734)
47. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B,. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004; 23 (29): 4993-5003. (Pubitemid 38938732)
48. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P,. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29 (1): 23-28.
49. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC,. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4 (12): 1371-1376. (Pubitemid 28553458)
50. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J, Sies H, Ackermann R, Kroncke KD,. Nitric oxide-mediated inhibition of androgen receptor activity: Possible implications for prostate cancer progression. Oncogene 2007; 26 (13): 1875-1884. (Pubitemid 46474631)
51. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ,. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: A phase I study. Lancet Oncol 2007; 8 (2): 111-118. (Pubitemid 46158370)